Advertisement

Tumor Biology

, Volume 37, Issue 2, pp 2137–2143 | Cite as

Apoptotic effect of tannic acid on fatty acid synthase over-expressed human breast cancer cells

  • Fangyuan Nie
  • Yan Liang
  • Bing Jiang
  • Xiabing Li
  • Hang Xun
  • Wei He
  • Hay Tong Lau
  • Xiaofeng Ma
Original Article

Abstract

Breast cancer is one of the most common cancers and is the second leading cause of cancer mortality in women worldwide. Novel therapies and chemo-therapeutic drugs are urgently needed to be developed for the treatment of breast cancer. Increasing evidence suggests that fatty acid synthase (FAS) plays an important role in breast cancer, for the expression of FAS is significantly higher in human breast cancer cells than in normal cells. Tannic acid (TA), a natural polyphenol, possesses significant biological functions, including bacteriostasis, hemostasis, and anti-oxidant. Our previous studies demonstrated that TA is a natural FAS inhibitor whose inhibitory activity is stronger than that of classical FAS inhibitors, such as C75 and cerulenin. This study further assessed the effect and therapeutic potential of TA on FAS over-expressed breast cancer cells, and as a result, TA had been proven to possess the functions of inhibiting intracellular FAS activity, down-regulating FAS expression in human breast cancer MDA-MB-231 and MCF-7 cells, and inducing cancer cell apoptosis. Since high-expressed FAS is recognized as a molecular marker for breast cancer and plays an important role in cancer prognosis, these findings suggest that TA is a potential drug candidate for treatment of breast cancer.

Keywords

Tannic acid Fatty acid synthase Inhibit Apoptosis Breast cancer cell 

Notes

Acknowledgments

This work was supported by the Fusion of Science and Education Special Fund, College of Life Sciences, University of Chinese Academy of Sciences (KJRH2015-012); Application Basic Research Project of Qinghai Province (2015-ZJ-728); Youth Innovation Promotion Association, CAS; 2014 Youth National Natural Science Foundation of China (No. 31300292); The Key Program of “The Dawn of West China” Talent Foundation of CAS (2012); 2014 Youth National Natural Science Foundation of China (No.31300292); The Key Program of “The Dawn of West China” Talent Foundation of CAS (2012), as well as High-Tech Research and Development Program of Xinjiang (No. 201315108) and China Postdoctoral Science Foundation (No. 2013 M540785).

Conflicts of interest

None

References

  1. 1.
    Jemal A, Bray F, Center MM. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMedGoogle Scholar
  2. 2.
    Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, Cooper D, Gansler T, Lerro C, Fedewa S, LinC, Leach C, Cannady RS, Cho H, Scoppa S, Hachey M, Kirch R, Jemal A, Ward E Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012;62:220–41.Google Scholar
  3. 3.
    Sebastian KS, Thampan RV. Differential effects of soybean and Fenugreek extracts on the growth of MCF-7 cells. Chem Biol Interact. 2007;17:135–43.CrossRefGoogle Scholar
  4. 4.
    Abe I, Umehara K, Morita R. Green tea polyphenols as potent enhancers of glucocorticoid-induced mouse mammary tumor virus gene expression. Biochem Biophys Res Commun. 2001;281:122–5.CrossRefPubMedGoogle Scholar
  5. 5.
    Uchiumi F, Sato T, Tanuma S. Identification and characterization of a tannic acid-responsive negative regulatory element in the mouse mammary tumor virus promoter. J Biol Chem. 1998;273:12499–508.CrossRefPubMedGoogle Scholar
  6. 6.
    Jiang Y, Satoh K, Aratsu C, Kobayashi N, Unten S, Kakuta H, Kikuchi H, Nishikawa H, Ochiai K, SakagamiH Combination effect of lignin F and natural products. Anticancer Res. 2001;21:965–70.Google Scholar
  7. 7.
    Devi MA, Das NP. In vitro effects of natural plant polyphenols on the proliferation of normal and abnormal human lymphocytes and their secretions of interleukin-2. Cancer Lett. 1993;69:191–6.CrossRefPubMedGoogle Scholar
  8. 8.
    Ramanathan R, Tan CH, Das NP. Cytotoxic effect of plant polyphenols and fat-soluble vitamins on malignant human cultured cells. Cancer Lett. 1992;62:217–24.CrossRefPubMedGoogle Scholar
  9. 9.
    Sakagami H, Jiang Y, Kusama K, Atsumi T, Ueha T, Toguchi M, Iwakura I, Satoh K, Ito H, Hatano T,Yoshida T Cytotoxic activity of hydrolyzable tannins against human oral tumor cell lines—a possible mechanism. Phytomedicine. 2000;7:739–47.CrossRefGoogle Scholar
  10. 10.
    Pan MH, Lin JH, Lin-Shiau SY, Lin JK Induction of apoptosis by penta-O-galloyl-β-D-glucose through activation of caspase-3 in human leukemia HL-60 cells. Eur J Pharmacol. 1999;381:171–83.CrossRefPubMedGoogle Scholar
  11. 11.
    Wang CC, Chen LG, Yang LL. Cuphiin D1, the macrocyclic hydrolyzable tannin induced apoptosis in HL- 60 cell line. Cancer Lett. 2000;149:77–83.CrossRefPubMedGoogle Scholar
  12. 12.
    Yang LL, Lee CY, Yen KY. Induction of apoptosis by hydrolyzable tannins from Eugenia jambos L. on human leukemia cells. Cancer Lett. 2000;157:65–75.CrossRefPubMedGoogle Scholar
  13. 13.
    Alo PL, Visca P, Marci A, Mangoni A, Botti C, Di Tondo U Expression of fatty acid synthase (FAS) as a predictor of recurrence in stage I breast carcinoma patients. Cancer. 1996;77:474–82.CrossRefPubMedGoogle Scholar
  14. 14.
    Milgraum LZ, Witters LA, Pasternack GR, Kuhajda FP Enzymes of the fatty acid synthesis pathway are highly expressed in in situ breast carcinoma. Clin Cancer Res. 1997;3:2115–20.PubMedGoogle Scholar
  15. 15.
    Epstein JI, Carmichael M, Partin AW. OA-519 (fatty acid synthase) as an independent predictor of pathologic state in adenocarcinoma of the prostate. Urology. 1995;45:81–6.CrossRefPubMedGoogle Scholar
  16. 16.
    Swinnen JV, Roskams T, Joniau S, Van Poppel H, Oyen R, Baert L, Heyns W, Verhoeven G Overexpression of fatty acid synthase is an early and common event in the development of prostate cancer. Int J Cancer. 2002;98:19–22.CrossRefPubMedGoogle Scholar
  17. 17.
    Pizer ES, Lax SF, Kuhajda FP, Pasternack GR, Kurman RJ Fatty acid synthase expression in endometrial carcinoma: correlation with cell proliferation and hormone receptors. Cancer. 1998;83:528–37.CrossRefPubMedGoogle Scholar
  18. 18.
    Gansler TS, Hardman W, Hunt DA, Schaffel S, Hennigar RA Increased expression of fatty acid synthase (OA-519) in ovarian neoplasms predicts shorter survival. Hum Pathol. 1997;28:686–92.CrossRefPubMedGoogle Scholar
  19. 19.
    Rashid A, Pizer ES, Moga M, Milgraum LZ, Zahurak M, Pasternack GR, Kuhajda FP, Hamilton SR Elevated expression of fatty acid synthase and fatty acid synthetic activity in colorectal neoplasia. Am J Pathol. 1997;150:201–8.PubMedPubMedCentralGoogle Scholar
  20. 20.
    Visca P, Sebastiani V, Botti C, Diodoro MG, Lasagni RP, Romagnoli F, Brenna A, De Joannon BC,Donnorso RP, Lombardi G, Alo PL Fatty acid synthase (FAS) is a marker of increased risk of recurrence in lung carcinoma. Anticancer Res. 2004;24:4169–73.PubMedGoogle Scholar
  21. 21.
    Orita H, Coulter J, Tully E, Kuhajda FP, Gabrielson E Inhibiting fatty acid synthase for chemoprevention of chemically induced lung tumors. Clin Cancer Res. 2008;14:2458–64.CrossRefPubMedGoogle Scholar
  22. 22.
    Alo PL, Amini M, Piro F, Pizzuti L, Sebastiani V, Botti C, Murari R, Zotti G, Di Tondo U Immunohistochemical expression and prognostic significance of fatty acid synthase in pancreatic carcinoma. Anticancer Res. 2007;27:2523–7.PubMedGoogle Scholar
  23. 23.
    Walter K, Hong SM, Nyhan S, Canto M, Fedarko N, Klein A, Griffith M, Omura N, Medghalchi S, KuhajdaF, Goggins M Serum fatty acid synthase as a marker of pancreatic neoplasia. Cancer Epidem Biomar. 2009;18:2380–5.Google Scholar
  24. 24.
    Kuhajda FP. Fatty acid synthase and cancer: new application of an old pathway. Cancer Res. 2006;66:5977–80.CrossRefPubMedGoogle Scholar
  25. 25.
    Fan HJ, Wu D, Tian WX, Ma XF Inhibitory effects of tannic acid on fatty acid synthase and 3T3-L1 preadipocyte. Biochimica et Biophysica Acta. 1831;2013:1260–6.Google Scholar
  26. 26.
    Wang X, Tian W. Green tea epigallocatechin gallate: a natural inhibitor of fatty-acid synthase. Biochem Biophys Res Commun. 2001;288:1200–6.CrossRefPubMedGoogle Scholar
  27. 27.
    Aggarwal BB, Shishodia S. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol. 2006;71:1397–421.CrossRefPubMedGoogle Scholar
  28. 28.
    Choi WI, Jeon BN, Park H, Yoo JY, Kim YS, Koh DI, Kim MH, Kim YR, Lee CE, Kim KS, Osborne TF, Hur MW Proto oncogene FBI-1 (Pokemon) and SREBP-1 synergistically activate transcription of fatty-acid synthase gene (FASN). J Biol Chem. 2008;283:29341–54.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Wang Y, Tian WX, Ma XF. Inhibitory effects of onion (Allium cepa L.) extract on proliferation of cancer cells and adipocytes via inhibiting fatty acid synthase. Asian Pac J Cancer Prev. 2012;13:5573–9.CrossRefPubMedGoogle Scholar
  30. 30.
    Menendez JA, Mehmi I, Atlas E, Colomer R, Lupu R Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB. Int J Oncol. 2004;24:591–608.PubMedGoogle Scholar
  31. 31.
    Booth BW, Inskeep BD, Shah H, Park JP, Hay EJ, Burg KJ Tannic Acid preferentially targets estrogen receptor-positive breast cancer. Int J Breast Cancer. 2013;2013:369609.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Landis-Piwowar KR, Milacic V, Chen D, Chen D, Yang H, Zhao Y, Chan TH, Yan B, Dou QP The proteasome as a potential target for novel anticancer drugs and chemosensitizers. Drug Resist Updat. 2006;9:263–73.CrossRefPubMedGoogle Scholar
  33. 33.
    Bendell J, Goldberg RM. Targeted agents in the treatment of pancreatic cancer: history and lessons learned. Curr Opin Oncol. 2007;19:390–5.CrossRefPubMedGoogle Scholar
  34. 34.
    Carver JR, Shapiro CL, Ng AA, Jacobs L, Schwartz C, Virgo KS, Hagerty KL, Somerfield MR, VaughnDJ ASCO Cancer Survivorship Expert Panel, American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. J Clin Oncol. 2007;25:3991–4008.Google Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Fangyuan Nie
    • 1
  • Yan Liang
    • 2
  • Bing Jiang
    • 1
  • Xiabing Li
    • 3
  • Hang Xun
    • 3
  • Wei He
    • 4
  • Hay Tong Lau
    • 4
  • Xiaofeng Ma
    • 1
  1. 1.College of Life SciencesUniversity of Chinese Academy of SciencesBeijingChina
  2. 2.School of Kinesiology and HealthCapital University of Physical Education and SportsBeijingChina
  3. 3.State Forestry AdministrationInternational Centre for Bamboo and Rattan Academy of Bioresource UtilizationBeijingChina
  4. 4.Gaubau Kender (Aletai, Xinjiang) Limited CompanyAletaiChina

Personalised recommendations